No profile data available.
ARS Pharmaceuticals, Inc. (SPRY) is a healthcare company in the allergy treatment pharmaceuticals industry, based in San Diego, United States, with about 195 full-time employees.
It reported revenue of $84.28 million for fiscal year 2025, down 5.5% from fiscal year 2024, and net income of -$171.30 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $33.66 million, up 114.2% from a year before. United States was its largest region in fiscal year 2025, with 86% of revenue. Its market capitalization was $420.66 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals reported $84.28 million in revenue for fiscal year 2025, down 5.5% from $89.15 million in fiscal year 2024. In Q2 2026 revenue was $33.66 million.
United States: 86% of revenue by region in fiscal year 2025, followed by Rest of World (14%).
$420.66 million as of October 9, 2026.
Listed companies of a similar size in the same industry (allergy treatment pharmaceuticals) include Rapt Therapeutics, Inc. (RAPT), DBV Technologies S.a. (DBVT), Nasus Pharma Ltd. (NSRX).